A U.S. House of Representatives subcommittee met April 27 to hear insight and recommendations from a panel of expert witnesses on how to improve U.S. biosafety and pathogen research in light of concerns surrounding the origins of COVID-19.
The COVID-19 epidemic has challenged conventional thinking about biosafety, leading a growing number of scientists to reconsider the danger of prospecting for unknown viruses and other research with pathogens.